Weight‑Loss Drugs Like Ozempic and Wegovy May Boost Male‑Pattern Hair‑Loss Risk, New Genetic Study Shows

Popular GLP‑1 medicines such as Ozempic, Wegovy and the newer Zepbound have been hailed for their ability to curb appetite and help people shed pounds. But a fresh investigation from NYU Langone Health suggests there might be a hidden side‑effect for some men – a slightly higher chance of losing hair.

The researchers zeroed in on the GLP1R gene, the part of our DNA that dictates how many GLP‑1 receptor proteins our bodies make. By comparing variations in this gene with genetic markers already known to cause androgenetic alopecia (that’s the scientific term for male‑pattern hair loss), they spotted a pattern.

Men who naturally carry GLP1R variants that push receptor levels upward were about 7 % more likely to develop the classic receding‑hair‑line and thinning‑crown look. The jump isn’t huge, but it’s statistically solid enough to raise eyebrows.

What’s interesting is that the link held up even after the team adjusted for other culprits that can mess with scalp health – high blood pressure, insulin resistance and even lower testosterone levels. Those factors are often blamed for hair shedding, yet the GLP‑1 connection stuck around.

So, are the drugs themselves the cause? Not exactly. GLP‑1 agonists have long been associated with temporary hair shedding, which many users attribute to the rapid weight loss that follows a new regimen. In most cases, hair regrows once the body finds a new, stable weight.

The new data, however, hint at a deeper story: a genetic predisposition that might make certain men more vulnerable when they start a GLP‑1 drug. “Our study provides the first genetic link between GLP‑1 use and an increased risk of male‑pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically,” explains senior investigator Lynn Petukhova, PhD, of NYU Grossman School of Medicine.

Petukhova believes this could eventually help clinicians flag patients who are at higher risk before writing a prescription. Imagine a quick genetic screen that says, “Hey, you might want to keep an eye on your hair if you start Ozempic.” In the longer run, the insight could also pave the way for combo‑therapies that both manage weight and protect follicles.

That said, the researchers caution they still don’t know the exact biological mechanism. Does GLP‑1 activity tug at the hair‑follicle cycle directly, or is it an indirect effect through blood‑flow changes? And does the same risk apply to women? Those questions will need more lab work.

To reach their conclusions, the team mined publicly available genetic repositories. One key source was the eQTLGen database, containing data from roughly 31,600 mostly White participants, and another was the Complex Traits Genetics database with over 200,000 subjects. All participants were of European ancestry, a detail that limits how broadly the findings can be applied.

Androgenetic alopecia is pretty common – about half of White men over 50 experience it, and a similar share of White women after menopause notice thinning. Meanwhile, a recent survey says roughly 12 % of Americans have tried GLP‑1 drugs for weight loss, a number that includes about one‑in‑five women between 50 and 64.

Since the FDA first approved Ozempic in 2020, prescriptions have more than tripled, reflecting the drug’s popularity. That surge makes any potential side‑effect worth watching.

The study was funded by NIH grants R01AR080796 and K01AR075111. Some authors disclosed past consulting work with pharmaceutical companies that make hair‑loss treatments – a standard transparency practice managed by NYU Langone’s policies.

In short, if you’re considering Ozempic, Wegovy or a similar GLP‑1 agent, it might be wise to discuss your family’s hair‑loss history with your doctor. While the risk is modest, being aware can help you make an informed choice.